Long-term outcomes of rituximab treatment for primary membranous nephropathy

Long-term real-world cohorts confirm rituximab as an effective first-line therapy for primary membranous nephropathy, inducing complete or partial remission in roughly two-thirds to over 80% of patients with excellent multi-year renal survival and a favorable safety profile.